AI-generated analysis. Always verify with the original filing.
Exact Sciences Corporation announced record fourth quarter and full year 2025 financial results, including total revenue of $878 million for Q4 2025 and $3.25 billion for full year 2025. The company also provided updates on its pending merger with Abbott Laboratories, platform advancements, and clinical study results for its cancer screening and diagnostic tests.
Event Type
Disclosure
Voluntary
Variant
8-K
Other Events
| Metric | Value | Basis |
|---|---|---|
| Revenue | $878.00 | |
| Screening Revenue | $695.00 | |
| Precision Oncology Revenue | $183.00 | |
| Gross Margin | 70% | GAAP |
| Adjusted Gross Margin | 73% | Non-GAAP |
| Net Loss | $86.00 | GAAP |
| Diluted EPS | $-0.45 | GAAP |
| Adjusted EBITDA | $63.00 | Non-GAAP |
| Adjusted EBITDA Margin | 7% | Non-GAAP |
Acquisition / Disposition